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Agnoprotein is one of the key regulatory proteins of polyomaviruses, including JCV, BKV and SV40 and is
required for a productive viral life cycle. We have recently reported that agnoprotein forms stable dimer/
oligomers mediated by a predicted amphipathic α-helix, spanning amino acids (aa), 17 to 42. Deletion of
the α-helix renders a replication incompetent virus. Here, we have further characterized this region by a
systematic deletion and substitution mutagenesis and demonstrated that a Leu/Ile/Phe-rich domain,
(spanning aa 28–39) within α-helix is indispensable for agnoprotein structure and function. Deletion of
aa 30–37 severely affects the dimer/oligomer formation and stable expression of the protein. Mutagen-
esis data also indicate that the residues, 34–36, may be involved in regulation of the splicing events of
JCV transcripts. Collectively, these data suggest that the Leu/Ile/Phe-rich domain plays critical roles in
agnoprotein function and thus represents a potential target for developing novel therapeutics against JCV
infections.
& 2013 Elsevier Inc. All rights reserved.Introduction
Proteins fulﬁll many complex functions through highly speciﬁc
interactions with their binding partners. These interactions can
occur between two identical proteins (homo-dimerization/oligo-
merization); or between two or more different proteins (hetero-
dimerization/oligomerization). Such interactions provide the par-
ticipant proteins speciﬁcity and diversity to perform their func-
tions successfully in many different biological processes including
DNA replication, gene transcription and regulation of different
pathways.
Viruses are obligatory intracellular parasites and rely heavily on
the mechanisms and functions provided by the host cells for their
propagation. Some viruses encode a limited number of regulatory
proteins and yet successfully complete their replication cycle,ll rights reserved.suggesting a multi-functional nature for these proteins. This
multi-functionality mostly stems from their ability to form diverse
but higher ordered dimeric, heteromeric or oligomeric structures.
There are many examples of such structures among the viral
proteins that have been reported in the literature, including
human immunodeﬁciency virus 1 (HIV-1) proteins (Rev, Vpr, Vif
and Vpu) (Bernacchi et al., 2011; Bourbigot et al., 2005; Daugherty
et al., 2010a, 2010b; Lu et al., 2010), Hepatitis C virus nonstructural
protein 4B (Gouttenoire et al., 2010), Ebola virus VP40 (Hoenen
et al., 2010), and large T-antigen (LT-Ag) of polyomaviruses (Cuesta
et al., 2010; Foster and Simmons, 2010). Recently, agnoprotein of
polyomaviruses was also shown to operate in this fashion. We
have reported the formation of highly stable dimeric/oligomeric
structures by the agnoprotein of JC virus (JCV), BK virus (BKV) and
simian virus 40 (SV40), and roughly mapped the region respon-
sible for this phenomenon to amino acids (aa) spanning from 17 to
42 for JCV agnoprotein (Saribas et al., 2011).
JCV agnoprotein is a small (71 aa long), multifunctional,
regulatory protein encoded by the late coding region of the viral
A. Sami Saribas et al. / Virology 443 (2013) 161–176162genome and was previously shown to interact with a number of
cellular and viral proteins, including p53 (Darbinyan et al., 2002),
YB-1 (Safak et al., 2002), FEZ1 and HP1-α (Okada et al., 2005), JCV
small t-antigen (Sm t-Ag) (Sariyer et al., 2008) and JCV large
T-antigen (LT-Ag) (Safak and Khalili, 2001). It has been implicated
in many different aspects of the JCV life cycle, including viral
transcription (Safak and Khalili, 2001), replication (Safak and
Khalili, 2001), functioning as viroporin (Suzuki et al., 2010),
encapsidation (Sariyer et al., 2006) and interfering with the
process of exocytosis (Johannessen et al., 2011). In addition, this
protein was found to deregulate cell cycle progression, where cells
that stably express agnoprotein largely accumulate at the G2/M
phase of the cell cycle (Darbinyan et al., 2002). Despite these
previous reports and intense research, the regulatory function of
agnoprotein in viral replication is not fully understood.
JCV agnoprotein shows a high degree of sequence identity and
similarity to that of SV40 and BKV (Safak et al., 2001). For example,
there is a 60% identity and a 79% similarity between JCV and SV40
agnoprotein sequences respectively, and 82% and 93% respectively
between JCV and BKV agnoprotein (Altschuler, 1999). SV40 and
BKV agnoprotein, like JCV agnoprotein, have also been previously
implicated in different aspects of viral replication cycle (Alwine,
1982; Haggerty et al., 1989; Hay et al., 1982; Hou-Jong et al., 1987;
Johannessen et al., 2008; Margolskee and Nathans, 1983; Moens
et al., 2011; Myhre et al., 2010; Ng et al., 1985; Unterstab et al.,
2010).
Expression of agnoprotein is required for the successful propa-
gation of Orthopolyomaviruses, including JCV, BKV and SV40,
because an agnoprotein null mutant of each virus is unable to
sustain the replication cycle although mutant viruses were shown
to be successfully released from the infected cells (Myhre et al.,
2010; Sariyer et al., 2011). Most importantly, even the constitutive
expression of LT-Ag, required for polyomavirus DNA replication, is
not sufﬁcient to sustain an efﬁcient viral propagation cycle in the
absence of agnoprotein, which further emphasizes the importance
of agnoprotein in viral life cycle (Sariyer et al., 2011). Agnoprotein
mostly resides in cytoplasm with high concentrations accumulat-
ing in the perinuclear region of the infected cells. However, a small
amount of the protein is also consistently detected in the nucleus,
indicating a possible nuclear function for agnoprotein. In fact, our
recent DNA binding studies supported this idea demonstrating
that agnoprotein stimulates the DNA binding activity of LT-Ag
without directly interacting with DNA (Saribas et al., 2012). In
addition, we have also recently reported that agnoprotein forms
highly stable, SDS-resistant homodimers and oligomers; and the
17–42 aa region of the protein is responsible for this property
(Saribas et al., 2011). While the 3D structure of agnoprotein has
yet to be determined, computer modeling studies predict that the
17–42 aa, which is important for stable dimer/oligomer formation,
is involved in forming an amphipathic α-helical structure (Saribas
et al., 2011; Unterstab et al., 2010). This α-helical region contains a
Leu/Ile/Phe-rich domain between aa 28 and 39. All three Phe
residues (Phe31, Phe35 and Phe39) of JCV agnoprotein localize to
this Leu/Ile/Phe-rich domain along with two negatively charged
residues, Glu34 and Asp38. The Phe residues of JCV agnoprotein
appear to be involved in viral DNA replication (Saribas et al., 2012).
With respect to the function of Phe residues, the protein distribu-
tion studies with confocal microscopy showed that Phe39 residue
of BKV agnoprotein may play a role in localization of the protein
to the lipid droplets in infected cells (Unterstab et al., 2010). In
addition to in vitro stable dimer/oligomer formation, we have
recently reported to dimer formation in vivo in the infected cells
(Saribas et al., 2011). Suzuki et al. (2010) have also demonstrated
homodimer, homo-oligomer formation in vivo by JCV agnoprotein,
by employing intermolecular ﬂuorescence resonance energy transfer
(FRET) and chemical cross-linking techniques.All these studies strongly suggest that the role of agnoprotein in
JCV replication cycle is critical and therefore in progressive multi-
focal leukoencephalopathy (PML), where JCV lytically infects the
oligodendrocytes in the central nervous system (CNS). This ubiqui-
tous human polyomavirus, JCV, infects a majority of the human
population worldwide (70–80%). Initial infection by this virus
is followed by a latency period. The reactivation of the virus mainly
occurs in patients with immunosuppressive conditions (1–5%),
including in those with cancer, organ transplant, and HIV-1/AIDS
(Berger, 2011; Berger and Concha, 1995; Major, 2010; Major et al.,
1992). In addition, a small percentage of patients with autoimmune
diseases such as multiple sclerosis (MS) and severe psoriasis
(Crohn's disease) who underwent an immunosuppressive therapy
with speciﬁc monoclonal antibodies (such as natalizumab, ritux-
imab and efalizumab) developed PML (Kleinschmidt-DeMasters
and Tyler, 2005; Langer-Gould et al., 2005; Van Assche et al.,
2005), suggesting that JCV is an important risk factor in these
patients.
In this study, we further examined the region of JCV agnopro-
tein responsible for formation of highly stable dimers and oligo-
mers using mutagenesis analysis. Our data demonstrate that
aa from 30 to 37 are sufﬁcient to confer the dimer/oligomer
formation property of agnoprotein. Consistent with our in vitro
mapping studies, functional studies demonstrated that the dele-
tion mutants, partially or completely missing the Leu/Ile/Phe-rich
domain, showed a signiﬁcant decrease in viral replication com-
pared to wild-type. In addition, transcriptional analysis studies
with the mutants revealed interesting defects in splicing patterns
of the viral late transcripts, suggesting a new novel function for
agnoprotein in JCV gene regulation at the post-transcriptional
level. Collectively, these ﬁndings demonstrate that the Leu/Ile/
Phe-rich domain is critically important for the dimer/oligomer
formation, stability and function of agnoprotein and thus repre-
sents a potential target for developing novel therapeutic agents for
progressive multifocal leukoencephalopathy.Results
Structural features of JC virus agnoprotein
Agnoprotein is one of the few regulatory proteins of JCV. It
possesses a highly basic aa composition with dominant Arg
(R) and Lys (K) residues, which are located at the amino and
carboxy ends of the protein (Fig. 1A). However, the middle portion
of the protein, encompassing aa from 28 to 39, is composed of
mostly hydrophobic residues, including Ile, Leu and Phe. The two
negatively charged residues Glu34 (E34) and Asp38 (D38) are also
located within this region. It is also interesting to note that all
three Phe residues (Phe31, Phe35 and Phe39) of JCV agnoprotein
are evenly dispersed and conﬁned within the Leu/Ile/Phe-rich
domain (Fig. 1A). We have recently analyzed the functional
importance of these Phe residues by site-directed mutagenesis
and the results showed that they have a combinatorial effect on
viral replication cycle (Saribas et al., 2012). The only cysteine
residue of agnoprotein (Cys40) is found towards the middle
portion of the protein right after the Leu/Ile/Phe-rich domain.
The three dimensional (3D) structure of agnoprotein is yet to be
resolved, however, computer modeling studies shown in Fig. 1B
using the I-TASSER progam (Roy et al., 2010) suggest that the Leu/
Ile/Phe-rich domain is involved in forming an amphipathic α-helix
(Fig. 1B and Fig. 1C). The Leu/Ile/Phe-rich domain is highly
conserved between agnoprotein of JCV, SV40 and BKV (Fig. 1D).
Three D modeling studies also suggest that carboxyl terminal half
of the protein encompassing aa from 40 to 71 as well as a small
portion of the amino terminal region of the protein may adopt an
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Fig. 1. Primary and predicted structural features of JCV agnoprotein. (A) Primary structure of agnoprotein. The Leu/Ile/Phe-rich domain (aa 28 to 39) is indicated. Previously
characterized phosphorylation sites (Ser7, Ser11 and Ser21) are also indicated (Sariyer et al., 2001). P stands for phosphorylation. (B) Predicted three dimensional (3D)
structure of agnoprotein was generated by I-TASSER program (Roy et al., 2010). This 3D structure indicates that the Leu/Ile/Phe-rich domain of agnoprotein is involved in
formation of α-helix (helical wheel). (C) The predicted α-helix has an amphipathic nature. Hydrophobic residues within the α-helix are clustered on one side of the helix and
the negatively and positively charged residues are on the opposite site. (D) Amino acid alignments of the Leu/Ile/Phe-rich domain among JCV, BKV and SV40 agnoprotein.
A. Sami Saribas et al. / Virology 443 (2013) 161–176 163intrinsically disordered conformation. That is, both regions lack
ﬁxed tertiary structures (Fig. 1B). This type of disordered con-
formation results from their high net charge and low overall
hydrophobic character (Dyson and Wright, 2005; Fink, 2005). It
has been suggested that such intrinsically disordered regions may
provide considerably high ﬂexibility to a protein to interact with
its various partners in a given time in a cellular environment so
that these types of proteins diversify and perhaps amplify their
functions (Dyson and Wright, 2005; Fink, 2005). For example, Ou
et al. (2012) recently demonstrated that adenovirus small protein
E4-ORF3 dimerizes/oligomerizes and eventually forms a multi-
valent functional matrix in the infected cells, which leads to
(Sariyer et al., 2011) the inactivation of several tumor suppressor
proteins including p53, TIM24, MRE11/Rad50/NBS1 (MRN) and
promyelocytic leukemia factor (PML). The majority of aa
sequences, except those located within the Leu/Ile/Phe-richdomain of agnoprotein, appears to have such intrinsically unstruc-
tured properties, which could play important roles in agnoprotein
functions with respect to interaction of the protein with its
partners in infected cells and thereby contribute signiﬁcantly to
the overall viral replication cycle.
Effect of amino- and carboxy-terminal deletion mutants on stable
dimer/oligomer formation by agnoprotein
We have recently reported formation of highly stable dimers/
oligomers for agnoprotein of JCV, BKV and SV40 and roughly
mapped the region responsible for this phenomenon, for JCV
agnoprotein to the aa from 17 to 42. In this study, we sought to
further deﬁne this region with respect to its ability to form stable
dimers and oligomers by employing a systematic mutagenesis
analysis of the region. We ﬁrst started by deleting the region from
A. Sami Saribas et al. / Virology 443 (2013) 161–176164the amino terminus of agnoprotein. For this purpose, different
amino terminal deletion mutants were fused to maltose binding
protein (MBP) as described in Materials and methods, expressed
in E. coli as MBP-Agno fusion protein and afﬁnity puriﬁed. As we
recently reported (Saribas et al., 2011), stable dimer and oligomer
formation by agnoprotein can be monitored by employing SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) under reducing
conditions followed by Coomassie blue staining (Fig. 2A). As we
previously reported, the full length (FL) agnoprotein readily forms
stable dimer and oligomers (Fig. 2A, lane 2) while MBP alone does
not (lane 1) (Saribas et al., 2011). Deletion of a 16 aa (17–71
construct, lane 3) or that of a 24 aa region (25–71 construct, lane 4)
or a 27 aa region (28–71 construct, lane 5) from the amino
terminal did not alter dimer/oligomer formation by agnoprotein.
In contrast, a slight increase was observed in the level of stable
dimers but not for the oligomers for each construct (17–71, 25–71
and 28–71 constructs). Further deletions of the amino terminus
residues including those from the Leu/Ile/Phe-rich domain greatly
reduced the ability of agnoprotein to form stable dimers and
oligomers (lanes 7–10). For instance, deletion of a 33 aa region
from the amino terminus resulted in not only the substantial loss
of the level of the dimeric structures (approximately in half)
but also completely abrogated the ability of the protein to form
oligomers (34–71 construct, lane 6), suggesting that aa 28 to 33
(ILIFLL) are required for stable oligomer formation and in the
meantime signiﬁcantly contribute to dimer formation (34–71
construct, lane 6). Similarly, further elimination of the amino acids
belonging to the Leu/Ile/Phe-rich domain from the amino terminus
completely abrogated oligomer formation property of agnoproteinMBP-Agno
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are barely detectable (35–71, 36–71 and 37–71 constructs, lanes
7–9, respectively). Elimination of the amino acid residues from the
amino terminus including the negatively charged Glu34 severely
affected dimer formation. Lastly, as previously reported (Saribas
et al., 2011), deletion of the ﬁrst 42 aa from the amino terminus
resulted in a complete abrogation of the formation of dimer and
oligomers (lane 10).
To further conﬁrm the ﬁndings from Fig. 2A, agnoprotein
was also subject to a systematic deletion process from the
carboxy terminal end and the resulting mutants were analyzed
for the stable dimer/oligomer formation as described for
Fig. 2A. As reported earlier (Saribas et al., 2011), a mutant,
which retains the ﬁrst 42 aa region, formed a comparable level
of dimers and oligomers to wild-type (Fig. 2B, compare lane
4 to 3). Note that this mutant contains the entireLue/Ile/Phe
domain and thus supports the idea that a mutant which retains
a complete Leu/Ile/Phe-rich domain is capable of forming
highly stable dimer and oligomers. In addition, consistent with
the results obtained from the amino terminal deletion
mutants, deletion of the region, containing 34EFLLDF39 motif,
from the carboxyl terminal of the Leu/Ile/Phe-rich domain but
retaining the ﬁrst 33 aa from the amino terminal resulted in a
phenotype that almost completely lost the ability to form
stable dimer or oligomers (1–33 construct, lane 5) conﬁrming
the role of 34EFLLDF39 in dimer/oligomer formation. As pre-
viously reported, a mutant retaining the ﬁrst 16 aa (construct
1–16, lane 6) does not have the ability to form either dimeric or
oligomeric structures (Saribas et al., 2011). Taken together,MBP-Agno
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with Ala on agnoprotein sequence. Then dimer/oligomer formation property of agnoprotein was tested as described for panel A. (C) Partial agnoprotein primary sequences
highlighting the Leu/Ile/Phe-rich domain are shown. (D) Summary of the results with respect to the ability of each protein to form dimer and oligomers relative to those
observed for WT as described for Fig. 2D. (E) Direct lysis of the internal deletion mutants of agnoprotein grown in bacteria in sample buffer and analysis of them by 8%-SDS-
PAGE followed by Coomassie blue staining. The expression plasmids of MBP-Agno WT (1–71) and agnoprotein internal deletion mutants fused to MBP (MBP-Agno Δ(34–36),
MBP-Agno Δ(30–37) and MBP-Agno Δ(17–42) were transformed into E. Coli and bacterial cultures (0.25 l each) were grown until OD¼0.5 at 37 1C in a culture shaker
(225 rpm). One milliliter of bacterial culture (induced with IPTG and uninduced) was pelleted by centrifugation (2 min. at 10,000 x g), resuspended in 50 mL ddH2O, treated
with 12.5 mL of SDS loading dye (5 ) and heated at 98 1C for 5 min. Samples were then spun at 15 krpm for 2 min. Twenty microliters of which were separated on an 8%
SDS-PAGE and analyzed by Coomassie blue staining. The bands corresponding to the induced proteins for each construct are indicated by rectangular brackets. In lane 2,
puriﬁed MBP alone (10 mg) was loaded as a control.
A. Sami Saribas et al. / Virology 443 (2013) 161–176 165these ﬁndings suggest that the Leu/Ile/Phe-rich domain of
agnoprotein plays a major role in formation of stable dimers
and oligomers. The levels of the dimeric and oligomeric forms
of amino terminal deletion mutants relative to those of wild-
type are summarized in Fig. 2D.Deletion of the Leu/Ile/Phe-rich domain resulted in the loss of stable
dimer/oligomer formation
We next attempted to further dissect the involvement of the
the Leu/Ile/Phe-rich domain in dimer/oligomer formation by
Table 1
The summary of dimer/oligomer formation by JCV Mad-1 WT agnoprotein in MBP fusion form [MBP-Agno (1–71)] and its
deletion/substitution mutants. Three plus signs (+++) represent the level of dimer/oligomer formation for the WT
agnoprotein. Four plus signs (++++) represent an increased level of dimer formation relative to that of WT. One plus sign (+)
represents a substantially reduced level of dimer formation relative to that of WT. Plus/minus sign (+/−) represents a signiﬁcantly
reduced level of dimer formation relative to that of WT and a minus sign (−) represents the absence of dimer/oligomer formation.
A. Sami Saribas et al. / Virology 443 (2013) 161–176166creating several internal deletion mutants of this region and
testing their ability in oligomerization assays. Deletion of three
internal aa (Glu34, Phe35 and Leu36) abrogated the ability of
agnoprotein to form stable oligomers and signiﬁcantly reduced the
level of dimer formation (40% decrease) (Fig. 3A, lane 4). Further
widening the deleted region within the Leu/Ile/Phe-rich domain of
agnoprotein, [encompassing the aa 30 to 37 (30IFLLEFLL37)]
resulted in a phenotype that failed to form both stable dimer
and oligomers; and even let the degradation of the monomers
(Fig. 3A, lane 5). In addition, as previously reported (Saribas et al.,
2011), a wide internal deletion of the region, spanning the amino
acids from 17 to 42 also completely abrogated the ability of
agnoprotein to form stable dimer, oligomers an monomers
(Fig. 3A, lane 6). Taken together, these internal deletion studies
further conﬁrm the essential role of the the Leu/Ile/Phe-rich
domain in oligomer formation and stability of agnoprotein.
Oligomer formation is lost and dimer formation is attenuated when
Glu34, Phe35 and Leu36 are deleted but both properties are restored
by Ala substitutions
Internal deletion of, Glu34, Phe35 and Leu36 residues, resulted
in the loss of oligomer formation and a substantial reduction in
dimer formation (Fig. 3A, lane 4). We wanted to further test
whether substitution of these three resides with Ala, which
is known to preserve the α-helical nature of a region within a
protein, would be able to restore dimer/oligomer formation. In this
substitution, our assumption was as follows: A triple Ala substitu-
tion will not destroy the α-helical nature of the Leu/Ile/Phe-rich
domain and therefore should not signiﬁcantly affect the dimer/
oligomer formation property of agnoprotein. To test this possibi-
lity, Glu34, Phe35 and Leu36 all were substituted with Ala residuesand the ability of the new mutant to form dimer/oligomers
relative to that of WT agnoprotein were investigated by SDS-
PAGE/Coomassie blue staining as described in legend to Fig. 3A.
Indeed, Ala substitution of three residues (Glu34, Phe35 and
Leu36) restored the oligomer formation ability of agnoprotein
compared to WT agnoprotein (Fig. 3B compare lanes 3 to 4)
although the levels of both were slightly lower than those
observed for WT agnoprotein. These results suggest following:
(i) The amphipatic nature of the Leu/Ile/Phe-rich domain and
(ii) reservation of the α-helical structure of the region are impor-
tant for the stable dimer/oligomer by agnoprotein. A summary of
the results from Fig. 3A and B are shown in Fig. 3D. Finally, the
behavior of all the agnoprotein mutants used in this study with
respect to their ability to form dimers and oligomers are summar-
ized in Table 1.
Agnoprotein becomes unstable when the Leu/Ile/Phe-rich domain is
altered
Elimination of majority of the Leu/Ile/Phe-rich domain [amino
acids from 30 to 37 (30IFLLEFLL37)] resulted in not only a complete
abrogation of stable dimer and oligomer formation but also greatly
reduced the level of monomer production by agnoprotein, sug-
gesting that the Leu/Ile/Phe-rich domain may also play a role in
stable expression of agnoprotein. To investigate this possibility,
bacterial cultures harboring different MBP-Agno deletion mutants
were induced (+) or uninduced (−) by IPTG; and bacterial cell
crude extracts were prepared by a rapid boiling and analyzed in a
10%-SDS-PAGE. As shown in Fig. 3E, the induced levels of MBP-
Agno WT (Fig. 3E, lane 4) or those of deletion mutants [Agno-Δ
(34–36), Agno-Δ(30–37) and Agno-Δ(17–42)] are readily detect-
able by Coomassie blue staining (Fig. 3E, lanes 6, 8 and 10,
Fig. 4. Immunoctyochemistry and Western blot analysis of different mutants of the Leu/Ile/Phe-rich domain of agnoprotein in the viral background. (A) SVGA cells (2106
cells/75 cm2 ﬂask) were transfected with Mad-1 Agno WT, Mad-1 Agno Ala(34–36), Mad-1 Agno Δ(34–36) and Mad-1 Agno Δ(30–37) genomes (8 mg each). The samples
were then processed for immunocytochemistry as described under Materials and methods. (B) Detection of agnoprotein by Western blotting. In parallel to the
immunocytochemical analysis in (A), whole-cell extracts were prepared from transfected/infected cells at indicated time points and 40 mg of protein extract were separated
on a 15% SDS-PAGE and transferred onto a nitrocellulose membrane for 10 min at 250 mA. Blots were then probed with anti-Agno primary polyclonal rabbit antibody
(1:1000 dilution) (Del Valle et al., 2002) for 2 h and washed with PBST three times and subsequently incubated with HRP-conjugated anti-rabbit secondary antibody for
45 min. Nonspeciﬁc binding of the secondary antibody was eliminated by three times washing of the blots with PBST with 10 min intervals. Blots were ﬁnally developed
using ECL plus kit (GE HealthCare) according to the Manufacturer's recommendations for detection of agnoprotein. Blots were also stripped and reprobed for anti-β actin
antibody (clone EP1123Y, rabbit monoclonal, Millipore) to monitor the equal loading for each lane. In lane 5 and 10, whole-cell extract prepared from untransfected SVGA
cells were loaded as a negative control (− Cont.). (C) Quantitation analysis of the Western blot bands done by a semi-quantitative densitometry method (using NIH Image
J program, http://rsb.info.nih.gov/ij) and presentation of the results in arbitrary units. The expression efﬁciency of each data point was presented relative to that of WT (15th
day data point).
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A. Sami Saribas et al. / Virology 443 (2013) 161–176168respectively). The disappearance of some or all of the monomers,
dimers and oligomers on SDS-PAGE on Fig. 3A and B, suggests that
these internal deletion mutants [Δ(30–370 and Δ(17–42)] are
readily produced upon induction by IPTG, but are rapidly degraded
during the protein preparation steps. It should be noted here, that
a sufﬁcient amount of protease inhibitors were included in the
lysis buffer to inhibit the all the proteases (Fig. 3A). Therefore, the
rapid degradation of these two proteins cannot be attributed to a
possible case where insufﬁcient amount of protease inhibitors was
added to the lysis buffer. As such, one possible explanation for the
rapid degradation of the internal deletion mutants of agnoprotein
would be that removal of the Leu/Ile/Phe-rich domain renders
agnoprotein an intrinsically unstable structure, thereby it leads
to degradation, which resembles a previously reported case for
heat shock proteins where they undergo a rapid self-degradation
process (Mitchell et al., 1985). In addition, there are, of course,
other possible ways for rapid degradation of agnoprotein mutants.W
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molecular-weight DNA containing both input and replicated viral DNA was isolated usi
restriction enzymes. Digested DNAwas separated on a 1% agarose gel, transferred onto a
DNA using a probe prepared from the JCV Mad-1 WT as a template. In lane 1 and 6, 2
(+Cont.). Replication assays were repeated several times and a representative data is
densitometry method (using NIH Image J program) and presentation of the results in ar
that of WT.One of these ways that proteins may also undergo such a
degradation process is the selective destruction of the misfolded
proteins (Goldberg, 2003). Such a degradation process is also likely
for agnoprotein mutants where mutations within agnoprotein
Leu/Ile/Phe-rich domain may lead to a misfolding process, which
are ultimately detected by bacterial cell degradation systems and
eliminated.
Analysis of the Leu/Ile/Phe-rich domain mutants by
immunocytochemistry
Next, we analyzed the effect of internal deletion mutants of the
Leu/Ile/Phe-rich domain on the expression proﬁle of agnoprotein
in the viral background by immunocytochemistry. SVG-A cells
were transfected/infected with either Mad-1 WT agnoprotein or a
Ala substitution mutant [Mad-1 Agno Ala (34–36)] or two deletion
mutants [[Mad-1 Agno Δ(34–36) or [Mad-1 Agno Δ(30–37)], ﬁxedT
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ivo. In parallel to immunocytochemical analysis of the mutants in Fig. 4A, the low-
ng Qiagen's spin columns (Ziegler et al., 2004), and digested with BamHI and DpnI
nitrocellulose membrane (Bio-Rad) and probed for detection of the newly replicated
ng of JCV Mad-1 WT linearized by BamHI digestion was loaded as positive control
shown here. (B) Quantitation analysis of Southern blots by a semi-quantitative
bitrary units. The replication efﬁciency of each data point was presented relative to
A. Sami Saribas et al. / Virology 443 (2013) 161–176 169the cell at 5th day posttransfection/infection and probed with
primary and secondary antibodies to detect agnoprotein and VP1
as described in the legend to Fig. 4A. Cells were then examined
under a ﬂuorescence microscope as described under Materials
and methods. As expected, WT agnoprotein displays a heavy
cytoplasmic distribution with high concentrations detected
around the perinuclear region (Safak et al., 2002) and a small
amount of the protein is also localized to the nucleus (Saribas
et al., 2012). However, the internal deletion of only three aa of
agnoprotein, Δ(34–36) from the viral background drastically
reduced the expression proﬁle of the protein to almost undetect-
able levels (Fig. 4A, Supplement 1). In addition, deletion of aa from
30 to 37 [Δ(30–37)] within the Leu/Ile/Phe-rich domain exhibited
a phenotype similar to that observed for a triple deletion mutant
[Δ(34–36)], suggesting that this region, aa from 34 to 36 are
critical for maintaining the stability of agnoprotein in a stable
conformation. In addition to the immunocytochemistry studies
shown in Fig. 4A, we also compared the expression proﬁles of
agnoprotein and VP1 at 5th day posttransfection/infection using a
lower magniﬁcation objective (10 ) (Supplement 1). ConsistentRelative level of M1 transcripts
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JCV late transcripts. The coding regions for agnoprotein, VP2, VP3 and VP1 are indicated
positions of the intron 1 and intron 2 are indicated. The probe region corresponding to V
prepared from untransfected (lane 1) and transfected/infected cells (SVG-A cells, lanes 2
the detection of the viral late transcripts using a radioactive probe corresponding to th
ampliﬁed, gel puriﬁed, quantitated, and labeled utilizing a ready-prime random labeling
detected by the probe are indicated as message M1 and message M2. (Middle) In parallel
ethidium bromide staining. Both 18S and 28S rRNA bands indicate the integrity of tot
radiolabeled probe speciﬁc to glyceraldehyde-3-phospate dehydrogenase (GAPDH), whic
of the Northern blot bands by a semi-quantitative densitometry method (using NIH Im
intensity of WT bands for M1 and M2 message for each ﬁgure was set to 100 and the owith the results from the high magniﬁcation studies (40 ,
Fig. 4A), we also observed an undetectable level of agnoprotein
expression for two deletion mutants, [Δ(30–37)] and [Δ(34–36)] at
low magniﬁcation studies (Supplement 1). Interestingly, the Ala
[(34–36)] substitution mutant expressed agnoprotein in a rela-
tively limited number of cells compared to WT (Supplement 1).
Observations from these immunocytochemistry assays are consis-
tent with our ﬁndings from the in vitro dimerization/oligomeriza-
tion assays (Fig. 3A). Additionally, our in vivo ﬁndings for the
[Δ(30–37)] mutant correlates with our in vitro dimer/oligomer
formation studies as well. It appears that deletion of majority of
the Leu/Ile/Phe-rich domain turned this protein into an intrinsi-
cally unstable structure (Fig. 3A, lane 5).
In parallel to the immunocytochemical studies, the expression
levels of each internal deletion mutant were also analyzed by
Western blotting. Whole-cell extracts were separated on a 15%
SDS-PAGE, transferred onto a nitrocellulose membrane and probed
with an anti-Agno antibody (Del Valle et al., 2002). As shown in
Fig. 4B and C, consistent with our results from immunocytochemistry
(Fig. 4A), the internal deletions [Δ(34–36) and Δ(30–37)] render18S rRNA
28S rRNA
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age J program) and presentation of the results in arbitrary units. The level of the
ther data points were calculated relative to WT and presented accordingly.
A. Sami Saribas et al. / Virology 443 (2013) 161–176170agnoprotein an unstable character and therefore it is hard to detect
them by Western blotting (Fig. 4B, lanes 3, 4, 8 and 9). Moreover, we
also addressed the question of whether substitution of these three
residues with Ala will restore a WT-like expression proﬁle for
agnoprotein. Ala residues are known to maintain the structure of
α-helical integrity if inserted into the region. These Ala substitutions
[Ala (34–36)] indeed restored the expression of agnoprotein to an
extent which was less than WT. Taken together; these protein
expression studies further conﬁrms the importance of the Leu/Ile/
Phe-rich domain in stable expression of agnoprotein.
Viral replication was signiﬁcantly reduced when alterations are made
in the Leu/Ile/Phe-rich domain of agnoprotein
We next examined the replication properties of agnoprotein
mutants relative to WT by DpnI assays, followed by Southern
blotting (Saribas et al., 2011, 2012). JCV Mad-1 WT and mutant
viral genomes were individually transfected/infected into SVG-A
cells and low molecular weight DNA was isolated at 5th and 15th
day posttransfection/infection as described in Materials and
methods. In order to obtain a single banded pattern on Southern
blots, DNA samples were digested with BamHI enzyme, which cuts
JCV genome once and thereby linearize the circular genome. DNA
samples were also digested with DpnI enzyme to remove input
DNA (bacterially produced and methylated), while keeping newly-
replicated viral DNA intact (Hirt, 1967). DNA samples were then
analyzed by Southern blotting using a probe prepared from JCV
Mad-1 genome as a template. As shown in Fig. 5A and B, the
replication efﬁciency of each mutant is indistinguishable from that
of WT (Fig. 5A, lanes 2–5) by the 5th day posttransfection/
infection. However, this drastically changed by the 15th day
posttransfection/infection. For example, two deletion mutants [Δ
(34–36) and Δ(30–37)] substantially lost their replication efﬁ-
ciency (90% and 70% respectively), suggesting the importance
of Leu/Ile/Phe-rich domain of agnoprotein for JCV replication. Both
ﬁndings correlate with our results from immunocytochemistry
and Western blot analysis studies (Fig. 4A and B), where it was
observed that agnoprotein expression was found to be at the
undetectable levels for both deletion mutants, [Δ(34–36) and
Δ(30–37)]. Additionally, we also tested the ability of Ala(34–36)
mutant in restoring the replication efﬁciency of the virus relative
to WT. We did not obtain a full recovery for this mutant compared
to WT (Fig. 5A, lane 8) again pointing out the importance of
residues within the agnoprotein dimerization domain for the viral
DNA replication, particularly to those located at aa 34–36 positions
(Glu34, Phe35 and Leu36). In fact, in support of this conclusion, a
recent report by our lab demonstrated that substitution of one of
these residues, Phe35, with Ala produced a phenotype that
replicated less efﬁciently than WT (Saribas et al., 2012).
Agnoprotein mutants display differential pattern of RNA expression
In vivo protein expression studies clearly demonstrated that
two of the deletion mutants, Δ(34–36) and Δ(30–37) did not
produce detectable level of agnoprotein (Fig. 3A). We further
investigate whether this phenomenon is regulated at transcrip-
tional or posttranscriptional level. To differentiate between these
two possibilities, SVG-A cells were separately transfected/infected
with either JCV WT or its agnoprotein mutants; and the total RNA
was isolated at the indicated time points, and analyzed by North-
ern blotting.
JC virus late coding region produces a polycistronic message
but computer-aided predictions suggest that this message may
also undergo an alternative splicing process and leads to the
production of two main distinct transcripts, message 1 (M1) and
message 2 (M2) as illustrated in Fig. 6A. There are also otherpossible splicing products generated from the JCV late transcripts
(Shishido-Hara et al., 2000). M1 contains the coding regions for all
four JCV late proteins, agnoprotein, VP2, VP3 and VP1 and splicing
for this message occurs between a splice donor site present right
after the 3′-coding region of agnoprotein and a splice acceptor site
located right before the 5′-coding region of VP2 (Fig. 6A). M2
message, on the other hand, harbors only the coding regions for
agnoprotein and VP1 and splicing for this transcript may occur
between a splice donor site present right after the 3′-coding region
of agnoprotein and a splice acceptor site located right before the
5′-coding region of VP1 (Fig. 6A). It is noteworthy that agnoprotein
coding region is present at the 5′-end of the both alternatively
spliced transcripts (Fig. 6A) and thus agnoprotein is expected to be
produced from each of these messages.
Northern blotting studies showed that both M1 and M2
transcripts are readily detectable for WT when a radioactive probe
corresponding to the VP1 coding region is used (Fig. 6A). It was
also consistently observed that the level of M1 is less than that of
M2 for WT (Fig. 6B, lanes 2 and 6; Supplement 2, lane 3). The
levels of M1 and M2 for the mutants, however, deviated signiﬁ-
cantly from this trend compared to WT and were differentially
regulated. For example, the deletion of a group of aa, (30IFL-
LEFLL37), from the dimerization domain of agnoprotein induced a
slight increase in the level of M1 compared to that of WT (lane
3 and 7). More interestingly, the removal of 3 aa [Glu34, Phe35 and
Leu36] from the same region of agnoprotein inﬂicted a more
drastic effect on the expression of M1 (lane 4) and we were unable
to obtain a detectable level of M1 for both data points (Fig. 6B,
lanes 4 and 8, Fig. 6C and D). Similarly, a signiﬁcant reduction was
observed in the level of [Ala(34–36)] mutant (Fig. 6B–D). It is
noteworthy to mention here that there is an intriguing discre-
pancy between Δ(30–37) and Δ(34–36) mutants with respect to
their M1 transcript expression levels, because it is expected that
the level of expression of M1 for both mutants would be, at least,
similar. This unexpected differential regulation of M1 is subject to
further investigation.
A differential level of regulation of M2 transcripts was also
observed for all three mutants. The levels of M2 for both WT
and the mutants were similar to one another at the ﬁrst data point
(5th day) but the deviations from this trend was more prominent
among the second data points (15th day) (Fig. 6B, lanes 7–9;
Fig. 6F). For example, the level of M2 for Δ(34–36) mutant reduced
to barely detectable levels relative to that of WT (Fig. 6B, lane 8;
Fig. 6F) and the levels of M2 for Δ(30–37) mutant and A(34–36)
mutant were also found to be signiﬁcantly decreased compared to
that of WT (lanes 7 and 9 respectfully). Taken together, all these
interesting results suggest that agnoprotein and/or its coding
sequences may be involved in regulation of the splicing patterns
of the viral late transcripts and the dimerization/oligomerization
domain of the protein may play an important role in this process.
We plan to further investigate the mechanism of the involvement
of agnoprotein in splicing of JCV transcripts using different
mutants of this region in the viral background. Furthermore, it
also appears that agnoprotein preferentially regulates mainte-
nance of the molar ratios between M1 and M2 transcripts (less
production of M1 than M2) and mutations within the dimerization
domain greatly affect this regulation. Aforementioned, both M1
and M2 have open reading frames for agnoprotein at their 5′-ends
and the expression of agnoprotein is expected to occur upon
translation of the each message. In fact, expression of agnoprotein
is readily detected for Ala(34–36) mutant, by Western blotting and
immunocytochemistry (Fig. 6A and B), although at relatively low
protein levels compared to WT. In contrast, we did not detect the
expression of agnoprotein for either Δ(34–36) or Δ(30–37) mutant
even though the levels of M2 transcripts are detectable on North-
ern blot at 5th day, suggesting that the regulation of the
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Fig. 7. PCR ampliﬁcation of the reversely transcribed (RT) M1 and M2 transcripts. (A) Graphical presentation of the JCV Mad-1 M1 transcript prior to splicing. Position of the
intron 1 between nucleotides 493 and 521 (Mad-1 numbering) is indicated. Location of the primers used in PCR also indicated with arrows. (B) PCR ampliﬁcation of 5′-end of
the RT products for M1 transcript. Two microliter of the RT reaction (described in Materials and methods) for each sample (5th and 15th day data points) were subjected to
PCR ampliﬁcation using Fail Safe™ DNA polymerase mix (Epicentre, PCR-pre mix F, Cat: SF99060) according to the recommendations of the manufacturer. The following
primers were used in the PCR reaction: Forward-(JCV Mad-1, 277–303 bp region): 5′-ATGGTTCTTCGCCAGCTGTCACGTAAG-3′. Reverse-(JCV Mad-1, 886–906 bp region): 5′-
AGCTTTACAATTATTTAATCCA-3′. PCR conditions were as follows: 94 1C, 1 min; 60 1C, 1 min, 72 1C for 2 min, 35 cycles. Ampliﬁed gene products were analyzed by agarose gel
electrophoresis (1.5%). Each RT product was also used to PCR-amplify GAPDH cDNA as a control for RT-PCR reactions using the following primers: GAPDH-Forward: 5′-
TTCTCCCCATTCCGTCTTCC-3′, GAPDH-Reverse: 5′-GTACATGGTATTCACCACCC-3′. The PCR conditions for GAPDH ampliﬁcation were the same as the one described for JCV
transcripts above. DNA bands of interest for each data point were cut out and puriﬁed using QIaquick gel extraction kit (Qiagen, Cat # 28704) and were sequenced by a
commercial vendor (Genewiz, http://www.genewiz.com). A closed arrow head points to a nonspeciﬁc PCR product. A hatched arrow head points to sample migration front.
(C) Graphical presentation of the 3′-end of the M1 transcript. Position of speciﬁc 5′- and the 3′-primers used in PCR is indicated. (D). PCR ampliﬁcation of the 3′-end of
the RT products for M1 transcript. Two microliter of the RT reaction for each sample (5th and 15th day data points) were subjected to PCR ampliﬁcation using the following
speciﬁc primers: Forward-(JCV Mad-1, 886–909 bp region): 5′-AGCTTTACAATTATTTAATCCA-3′ and Reverse-(JCV Mad-1, 2533–2517 bp region):
5′-TTACAGCATTTTTGTCT-3′. (E) Graphical presentation of the JCV Mad-1 M2 transcript prior and after splicing. Position of the intron 2 between nucleotides 493 and
1426 (Mad-1 numbering) is indicated. Location of the forward and reverse primers used in PCR also indicated. (F) PCR ampliﬁcation of the RT products for M2 transcript. Two
microliter of the RT reaction for each sample (5th and 15th day data points) were subjected to PCR ampliﬁcation using the following speciﬁc primers: Forward-(JCV Mad-1,
277–303 bp region): Forward-(JCV Mad-1, 277–303 bp region): 5′-ATGGTTCTTCGCCAGCTGTCACGTAAG-3′ and Reverse-(JCV Mad-1, 2533–2517 bp region): 5′-TTACAG-
CATTTTTGTCT-3′. The PCR ampliﬁcation, gel analysis and sequencing condition for each sample were the same as described for panel B samples. In lane 1 in panels B, D and F,
RT products from SVG-A cells (untransfected cells used as a negative control, - Cont.) was subjected to PCR ampliﬁcation as described for experimental samples. In lane 7 in
panels B, D and F, JCV Mad-1 WT genome (10 ng) was PCR-ampliﬁed using speciﬁc primers described for the experimental samples and used as a positive control, + Cont., in
gel analysis. Transf./Inf.: transfection/infection.
A. Sami Saribas et al. / Virology 443 (2013) 161–176 171expression of agnoprotein for the mutants occurs primarily at the
level of posttranscription rather than transcription. In other words,
agnoprotein is most likely produced but rapidly degraded in cells
transfected/infected with these two mutants. It should be also
noted here that variations observed in M1 and M2 levels for the
mutants cannot be attributed to experimental errors, such as
samples are not equally loaded onto the gels or to a possible
degradation of total RNA, because results from the control experi-
ments are self-evident and dismiss such possibilities (Fig. 6B).
Dimerization domain mutants show defects in splicing patterns of the
viral late transcripts
Results from the Northern blot analysis strongly suggest that
agnoprotein may be involved in the splicing events of the viraltranscripts. We sought to further examine this possibility by
RT-PCR analysis of the viral late transcripts followed by the DNA
sequencing of the RT-PCR products.
As mentioned earlier, JCV late genome produces polycistronic
transcripts. However, these transcripts may also undergo an alter-
native splicing process as predicted and produce two primary
messages due to removal of the intron 1 and intron 2 (Fig. 6A). We
investigated (i) whether these predicted splicing events occur for
WT and (ii) whether the mutations made at the dimerization
domain of agnoprotein show an effect on these two forms of the
splicing patterns of the viral late transcripts.
We ﬁrst examined the splicing pattern of M1 transcript, where
intron 1 is predicted to be spliced out (Fig. 7). The same RNA
samples used for Northern blotting were also utilized in RT-PCR as
described under legend for Fig. 7, using gene speciﬁc primers.
A. Sami Saribas et al. / Virology 443 (2013) 161–176172RT-PCR products were then analyzed on an agarose gel and DNA
bands of interest were excised, gel-puriﬁed and subjected to a DNA
sequence analysis. Sequencing data revealed that indeed the
splicing of the intron 1 occurs for WT as predicted, (Fig. 7B, lanes
3 and 10). A deletion mutant where aa from 30 to 34 are removed
[Δ(30–37)] also showed a splicing pattern similar to that observed
for WT (lanes 4 and 11). Interestingly, removal of three aa, Glu34,
Phe35 and Leu36 from aa 30–37 region (lanes 5 and 12) unex-
pectedly inhibited splicing of intron 1 from the M1 transcript. This
ﬁnding suggests that residues, Glu34, Phe35 and Leu36, individu-
ally or collectively are involved in regulation of splicing of JCV
transcripts. However, we cannot still explain the intriguing beha-
vior of this mutant compared to that of Δ(30–37) mutant, where
these three amino acids were also eliminated but obtained a
spliced form of the M1 transcript. Similarly, substitution of
Glu34, Phe35 and Leu36 with triple Ala residues also resulted in
a similar phenotype as observed for Δ(34–36) mutant. In other
words, we detected the unspliced forms of the M1 transcript for
both mutants (lanes 5 and 6).
In parallel, 3′-ends of the same late gene transcripts for WT and
the mutants were also subjected to analysis by RT-PCR using
speciﬁc primers as described in legend Fig. 7D. The sequence
analysis of the expected RT-PCR fragments (1650 bp) showed no
surprising results for WT and the mutants except that the level of
the RT-PCR products for Δ(34–36) mutant was observed to be
signiﬁcantly lower than both WT and other two mutants (Fig. 7D,
lanes 5 and 12), which is consistent with its M1 levels detected on
Northern blot (Fig. 6, lanes 4 and 8).
Next, we also analyzed the splicing patterns of M2 transcripts
in parallel to those for M1 by RT-PCR followed by DNA sequencing.
Sequencing data showed that the removal of the intron 2 from the
primary transcripts indeed occurs at the predicted splice junctions
between agnoprotein and VP1 for WT and agnoprotein mutants
(Fig. 7E and F). Note that we were unable to obtain a detectable
level of RT-PCR product for Δ(34–36) mutant under our RT-PCR
conditions, which is most likely due to extremely low levels of
speciﬁc RNA present at 15th day time point, consistent with the
Northern blotting data (Fig. 6, lane 8). Taken together, results from
RT-PCR and DNA sequencing are consistent with our ﬁndings from
the Northern blot analysis of the viral late transcripts for WT
and the mutants, demonstrating that agnoprotein is indeed
involved in the regulation of the splicing patterns of the viral late
transcripts and the dimerization domain of the protein appears to
play a critical role in this process. We will further investigate the
mechanism of this regulation by creating a combination of
different mutants of the dimerization domain in the viral back-
ground. In addition, we think that agnoprotein may also be
involved in regulation of the viral early transcripts, but it is subject
to further investigation.Discussion
Agnoprotein is a regulatory protein of Orthopolyomaviruses
(Johne et al., 2011), including JCV, BKV and SV40 and is essential
for the efﬁcient replication cycle of each virus. In the absence of its
expression, the rate of the viral replication is signiﬁcantly reduced
for each subsequent replication cycle. As a result, viral propagation
halts after 2 or 3 viral life cycles (Myhre et al., 2010; Saribas et al.,
2011; Sariyer et al., 2011). In addition, agnoprotein of all three
polyomaviruses, JCV, BKV and SV40 forms highly stable SDS-
resistant dimeric and oligomeric structures (Saribas et al., 2011),
the functions of which are currently unknown. However, it is
conceivable that such structures may provide considerable ﬂex-
ibility for agnoprotein to diversify its biological functions in the
infected cells.Our previous mapping studies demonstrated that aa from 17 to
42 are important for dimer/oligomer formation by agnoprotein
(Saribas et al., 2011). In the current study, we further characterized
the dimer/oligomer formation domain of agnoprotein by deletion/
substitution analysis followed by functional studies in the viral
background. We demonstrated that Leu/Ile/Phe-rich domain cor-
responding to aa from 28 to 39 play an essential role in stable
dimer/oligomer formation for agnoprotein. Speciﬁcally, aa span-
ning from 30 to 37 are sufﬁcient to confer this phenomenon
(Table 1). In vivo data demonstrated that, in the absence of aa
spanning from 34 to 36 or from 30 to 37, the mutant JC viruses
express agnoprotein poorly (Fig. 4A and B) and replicate at
relatively minimal levels compared to WT (Fig. 5A and B),
suggesting that Leu/Ile/Phe-rich domain plays an essential role in
protein function (Fig. 5A and B) and stability (Table 1). We further
investigated whether the undetectable levels of agnoprotein
expression is due to the regulation at the transcriptional or
posttranscriptional level by Northern blotting (Fig. 6B) and by
RT-PCR (Fig. 6) followed by DNA sequencing. Results from these
studies let to a novel observation with respect to the agnoprotein
function—involvement of the protein in viral gene regulation at
the post-transcriptional level. First of all, we detected two primary
transcripts namely M1 and M2 regarding the viral late gene
expression on Northern blot. RT-PCR studies and subsequent
DNA sequencing revealed that M1 transcript is responsible for
producing all the JCV late proteins, agnoprotein, VP1, VP2 and VP2
(Fig. 6A). M2 transcripts on the other hand are associated with the
production of only agnoprotein and VP1 (Fig. 6A). The novelty of
our ﬁndings is several fold: (i) Mutations within the dimerization
domain of agnoprotein may lead to defects in the splicing patterns
of the viral late transcripts. (ii) The levels of M1 and M2 appear to
be differentially regulated by agnoprotein and the dimerization/
oligomerization domain of the protein appears to play a critical
role in this process. (iii) The level of M1 is consistently found to be
lower than that of M2 for WT (Fig. 6A, Supplement 2) in the
infected cells. These ﬁndings may translate into the viral replica-
tion cycle as follows: One of the ways that JCV tries to produce a
higher number of infectious particles in infected cells is through
the regulation of the molar ratios between VP2/VP3 and VP1. It is
known that the VP2 and VP3 are located at the inner layers of a
virion and VP1 forms the outer layer of an infectious viral particle
(Saribas et al., 2010). If one examines the relationship between the
size and volume in consideration of a virion, it is apparent that JCV
needs less molar amount of VP2/VP3 than VP1 to make up the
inner layers of a virion due to the space limitation. Our ﬁndings
from the Northern blot and RT-PCR studies are consistent with
such an analysis. That is, in the absence of a functional agnopro-
tein, JCV would not be able to maintain the molar ratios between
the VP2/VP3 and VP1, which then leads to a defective viral
replication cycle. In other words, the efﬁciency of the virion
formation is no longer regulated and the virus may produce
mostly empty capsids, as we have previously reported (Sariyer
et al., 2011).
Structurally speaking, agnoprotein is not alone among viral
proteins with respect to forming dimer and oligomers. Like
agnoprotein, there are many examples in the literature of viral
proteins that form dimers and oligomers, including human immu-
nodeﬁciency virus 1 (HIV-1) proteins (Rev, Vpr, Vif and Vpu)
(Bernacchi et al., 2011; Bourbigot et al., 2005; Daugherty et al.,
2010a, 2010b; Lu et al., 2010), Hepatitis C virus nonstructural
protein 4B (Gouttenoire et al., 2010), Ebola virus VP40 (Hoenen
et al., 2010), and polyomavirus LT-Ag (Cuesta et al., 2010; Foster
and Simmons, 2010). For example, Rev is an RNA binding protein
and forms stable dimer/oligomers that regulate the transport
of unspliced or partially spliced RNA molecules from nucleus to
cytoplasm. Rev initially binds to a highly structured 350
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viral introns, in dimeric forms. Recently resolved crystal structure
of Rev-RNA complex demonstrates that dimeric forms of Rev
cooperatively bind to viral RNA to form an elegant hexameric unit
complexed with RNA. This hexameric complex has 500-fold higher
afﬁnity to RRE than any monomeric Rev molecule. The Rev-RRE
nucleoprotein complex then targets the host export factor Crm1
(XpoI), which shuttles the Rev-RNA complex to cytoplasm. In the
cytoplasm, Rev unloads its cargo and free Rev is reimported into
the nucleus for further rounds of nuclear export of HIV-1 RNA
(Cullen, 2003a, 2003b). As in the case of Rev, we think that dimeric
and oligomeric forms of agnoprotein play important roles in its
function—perhaps in the transport of JCV transcripts from nucleus
to cytoplasm or in the splicing process of the viral transcripts. We
will further investigate such possibilities.
In addition to possessing predicted α-helical domains (Fig. 1B),
agnoprotein sequences display intrinsically disordered structures.
A prime example of such intrinsically disordered structural viral
proteins is the HIV-1 Vif protein. This protein plays important roles
in the viral pathogenesis by facilitating the degradation of APO-
BEC3G, an endogenous cellular inhibitor (cytosine deaminase) of
HIV-1 replication (Sheehy et al., 2002). These types of proteins,
which are known to have extensive regions that lack a ﬁxed
tertiary structure, have high net charge and low overall hydro-
phobicity, which are the main characteristics of such proteins
(Dunker et al., 2005; Dyson and Wright, 2005; Fink, 2005; Uversky
et al., 2005). It is suggested that these intrinsically disordered
regions provide a considerable ﬂexibility to a protein to interact
with multiple but structurally diverse partners in the host cells
during the viral infection cycle. Predictions from our computer
modeling studies indicate that a small portion of N-terminal and
C-terminal domains of JCV agnoprotein possess such intrinsic
disordered structures (Fig. 1B) (Saribas et al., 2011), implying that
these regions may indeed be the executioner domains of agno-
protein to interact with a variety of partners in the infected cells
and play signiﬁcant roles in agnoprotein function.
JCV, like other Orthopolyomaviruses including BKV and SV40,
encodes only a limited number of regulatory proteins, one of
which is agnoprotein, and yet it successfully goes through its
replication cycles. This suggests that regulatory proteins of JCV
fulﬁll more than one function to optimize the viral life cycle.
Published reports indicate that JCV agnoprotein is involved in
many aspects of viral replication cycle, including viral DNA
replication (Safak et al., 2001; Saribas et al., 2011) and transcrip-
tion (Safak et al., 2001, 2002; Sariyer et al., 2011). If this is the case,
then, the question arises “how is such a small protein like
agnoprotein able to achieve so many different functions despite
its small size?” It appears that different regions of agnoprotein are
involved in different functions. For instance, our recent protein–
protein interaction studies with agnoprotein and LT-Ag showed
that agnoprotein stimulates LT-Ag binding to the viral origin of
replication (Ori), through which it contributes to viral replication
cycle (Saribas et al., 2012). We also previously reported that
alterations in the protein kinase C (PKC) phosphorylation sites of
JCV agnoprotein (conversion of Ser7, Ser11 and Thr21 to Ala)
resulted in a phenotype that is unable to sustain the viral
replication cycle (Sariyer et al., 2006). Moreover, deletion of either
the intrinsically disordered C-terminal region (sequences from 51
to 71) (Akan et al., 2006) or that of internal sequences spanning
amino acids 17 to 42 (Saribas et al., 2011), which are involved in
dimer/oligomer formation by agnoprotein, resulted in phenotypes
that are replication incompetent. In this study, beside ﬁne map-
ping of the multimerization domain of agnoprotein, we have also
discovered a novel function for the protein-regulation of the
splicing patterns of the viral late transcripts and involvement of
the dimerization domain of the protein in this process. All theseﬁndings suggest a relationship between agnoprotein structure and
its role in splicing of the viral transcripts.
We also investigated the role of the multimerization domain of
JCV agnoprotein in viral replication cycle. Amino and carboxy
terminal; and internal deletion analysis studies revealed that the
Leu/Ile/Phe-rich domain of the protein encompassing amino acids
from 28 to 39 plays an essential role not only in stable dimer and
oligomer formation (Table 1) but also in stable expression of the
protein (Fig. 4A and B). Internal deletions of the Leu/Ile/Phe-rich
domain in the viral background signiﬁcantly hampered the agno-
protein expression (Fig. 4A and B) and viral DNA replication
(Fig. 5A and B). For example, deletion of only 3 aa [Δ(34–36)]
abrogated oligomer formation and reduced dimer formation in
half in vitro (Fig. 3A, lane 4). Further deletion of the region which
covers the most of the Leu/Ile/Phe-rich domain resulted in a
phenotype that is unable form either stable dimers or oligomers
[Δ(30–37)] in vitro (Fig. 3A, lane 5). Consistent with these in vitro
observations, in vivo studies with the internal deletion mutants
where the Leu/Ile/Phe-rich domain was altered [Δ(34–36) and Δ
(30–37)] showed that these internal deletion mutants considerably
lost their ability to replicate efﬁciently due to agnoprotein deﬁ-
ciency (Fig. 5A and B). Amino acid alignment studies showed that
the Leu/Ile/Phe-rich domain residues of agnoprotein are substan-
tially conserved among JCV, BKV and SV40 (Fig. 1D). Therefore, it is
conceivable that this region serves similar functions in the
agnoprotein of BKV and SV40 as well. As such, our results from
this study may have broad implications regarding the biology of
Orthopolyomaviruses.
Proteins play fundamental regulatory and structural roles in all
living organisms, including in viruses. Without their 3D structure, it
is difﬁcult to understand their function. We have attempted to obtain
the 3D crystal structure of bacterially expressed JCV agnoprotein
(MBP-Agno) several times with no success due to the fact that a
dynamic process of the conversion of monomers to dimers, then
dimers to oligomers (Saribas et al., 2011). We are currently, however,
in the process of obtaining its structure by NMR studies using
synthetic peptides as similar structural studies were previously
reported for HIV-1 Vpr (Bourbigot et al., 2005). The results from
these structural studies along with those reported in our current
work may provide us new opportunities to develop effective inhibi-
tors against the unique dimerization/oligomerization domain of JCV
agnoprotein to hamper the spread of the virus in PML.Materials and methods
Cell lines
SVG-A cell line was established by immortalization of the
primary human fetal glial cells with an origin-defective SV40
mutant (Major et al., 1985). This cell line does not express either
SV40 viral capsid proteins (VPs) or agnoprotein, but expresses SV40
LT-Ag and supports JCV propagation. Cells were grown in Dulbecco's
modiﬁed Eagle's medium (DMEM) supplemented with 10% heat-
inactivated fetal bovine serum (FBS) and antibiotics [penicillin/
streptomycin (100 mg/ml), ciproﬂoxacin (10 mg/ml]. Cells were
maintained at 37 1C in a humidiﬁed atmosphere supplemented
with 7% CO2.
Plasmid constructs
The cloning of pMAL-c5X-Agno (1–71), pMAL-c5X-Agno (1–16),
pMAL-c5X-Agno Δ(17–42), pMAL-c5X-Agno (17–71), pMAL-c5X-
Agno (1–42) and pMAL-c5X-Agno (43–71) constructs was previously
described (Saribas et al., 2011). Amino terminal [Agno (25–71),
Agno (28–71), Agno (34–71), Agno (35–71), Agno (36–71) and Agno
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agnoprotein were subcloned into NcoI/Eco RI sites of pMAL-c5X
bacterial expression vector to produce MBP-Agno fusion protein by
PCR-based cloning. Bluescript KS-JCV-Mad-1 WT plasmid was used
as a template for PCR ampliﬁcations. PCR products were ethanol-
precipitated, digested with NcoI and EcoRI restriction enzymes, gel
puriﬁed and ligated into pMAL-c5X bacterial expression vector (MBP
fusion system, NEB). The resulting plasmids were designated as
pMAL-c5X-Agno (25–71), pMAL-c5X-Agno (28–71), pMAL-C5X-
Agno (34–71), pMAL-c5X-Agno (35–71), pMAL-c5X-Agno (36–71),
pMAL-c5X-Agno (37–71) and pMAL-c5X-Agno (1–33). Amino acids
from 34 to 36 and from 30 to 37 were deleted from the virus
background by deletion mutagenesis using appropriate primers and
these plasmids was designated as Bluescript KS(+)-JCV Mad-1 Agno
Δ(34–36) and Bluescript KS(+)-JCV Mad-1 Agno Δ(30–37). Insertion
of the wild-type Mad-1 genome into the BamHI site of Bluescript KS
(+) vector was previously described (Sariyer et al., 2006). Amino
acids from 34 to 36 were substituted with Ala (E34AF35AL36A) in
the viral background (JCV Mad-1) using the Quik Change™ site–
directed mutagenesis kit (Agilent) using appropriate synthetic oligo-
nucleotides and designated as JCV Mad-1 Agno Ala(34–36). Each
mutant agnogene was then subcloned into NcoI/EcoRI sites of
pMAL-c5X vector and plasmids were designated as pMAL-c5X-
Agno Δ(34–36), pMAL-c5X-Agno Δ(30–37) and pMAL-c5X-Agno Ala
(34–36). The integrity of the whole viral genomes in the viral back-
grounds and the mutants made in each construct were veriﬁed by
DNA sequencing.
Expression and puriﬁcation of recombinant proteins
Bacterial expression plasmids [pMAL-pMAL-c5X alone, pMAL-c5X-
Agno (17–71), pMAL-c5X-Agno (25–71), pMAL-c5X-Agno (28–71),
pMAL-c5X-Agno (34–71), pMAL-c5X-Agno (35–71), pMAL-c5X-Agno
(36–71), pMAL-c5X-Agno (37–71), pMAL-c5X-Agno (43–71), pMAL-
c5X-Agno (1–42) and pMAL-c5X-Agno (1–33). pMAL-c5X-Agno Δ(34–
36), pMAL-c5X-Agno Δ(30–37) and pMAL-c5X-Agno Ala(34–36)] were
transformed into Escherichia coli DH5α strain and cultures were grown
in 100ml Luria–Bertani broth (LB) supplemented with ampicillin
(100 mg/ml) at 37 1C overnight. Next day, cultures were ﬁrst diluted
1:10 in fresh LB in 0.25 l supplemented with glucose (2 g/l) and
ampicillin (100 mg/ml); and grown at 37 1C until at an optical density
of 0.5 at 600 nm. Bacterial cultures were then induced with 0.3 mM
isopropyl-β-thiogalactopyranoside (IPTG) and incubated for an addi-
tional 2 h at 28 1C. Bacterial cultures were then harvested by centri-
fugation and the resulting pellet from the various MBP-Agno fusions
were each resuspended in amylose column buffer (20 mM Tris–HCl pH
7.4, 200 mM NaCl and 1mM EDTA). The cell suspension was then
incubated on ice for 30 min in the presence of lysozyme (0.5 mg/ml)
and protease inhibitor cocktail (Sigma), after which the cells were
lysed by sonication. Clear lysates were obtained after a high speed
centrifugation at 15,000 rpm (Thermo Scientiﬁc, F21-850y rotor).
The lysates were then incubated with 200 ml of amylose FF (fast ﬂow)
resin (1:1, buffer:beads) (New England Biolabs) prepared in amylose
column buffer overnight at 4 1C. MBP-Agno fusion proteins bound
amylose resins were washed with ﬁve column volumes of amylose
column buffer and were puriﬁed. Puriﬁed proteins were either stored
on beads at +4 1C or eluted with 10 mMmaltose prepared in the same
buffer and stored at +4 oC or −30 1C until use. The quality of the
proteins was analyzed by SDS-PAGE/Coomassie staining as described
previously (Saribas et al., 2011).
Indirect immunoﬂuorescence microscopy
Indirect immunoﬂuorescence microscopy studies were per-
formed as previously described (Sadowska et al., 2003; Sariyer
et al., 2011). Brieﬂy, SVG-A cells (2106 cells/75 cm2 ﬂask) wereseparately transfected/infected with different viral DNA (8 mg
each) as indicated in each respective ﬁgure legend. At 5th day
posttransfection, the cells were seeded at subconﬂuency on
polylysine-coated glass chamber slides. The next day, the cells
were washed twice with PBS, ﬁxed in cold acetone and incubated
with 5% bovine serum albumin in PBS for 2 h. Chamber slides were
then incubated with anti-agnoprotein primary polyclonal antibody
(1:200 dilution) (Safak et al., 2002) plus anti-VP1 primary mono-
clonal (pAB597) antibody (Saribas et al., 2011) (1:200 dilution)
overnight. Antibody dilutions and incubations were performed in
incubation buffer [PBS-0.01% Tween 20, (PBST)] buffer. Cells were
washed three times with PBST buffer for 10 min intervals and
subsequently incubated with a Rhodamine-conjugated goat anti-
mouse plus ﬂuorescein isothiocyanate (FITC)-conjugated goat anti-
rabbit secondary antibodies (BD biosciences) for 45 min. Finally,
slides were washed three times with PBST buffer, mounted, and
examined under a ﬂuorescence microscope (Nikon eclipse TE300;
objectives: 101.25 Ph1 DL and 40 /1.3 oil, plain ﬂour; eyepiece:
10 ; operating software: Slidebook 5.0.) for detection of JCV
agnoprotein and VP1.
Replication assays
Replication assays were carried out as previously described
(Sariyer et al., 2011). Brieﬂy, the plasmid constructs [Bluescript KS
(+)-JCV Mad-1 WT, Bluescript KS(+)-JCV Mad-1 Agno Δ(34–36),
Bluescript KS(+)-JCV Mad-1 Agno Δ(30–37) and Bluescript KS
(+)-JCV Mad-1 Agno Ala(34–36) were digested with BamHI to
liberate the viral genome inserts from the vector [Bluescript KS
(+)]. SVG-A cells (2106 cells/75 cm2 ﬂask) were then separately
transfected/infected each with the digested DNA (8 mg each) using
lipofectamine 2000 according to Manufacturer's recommendations
(Invitrogen). After 5 h incubation with the transfectants, cells were
washed with PBS and fed with DMEM supplemented with 10% FBS
and 1% ampicillin/streptomycin. Media were replenished every
three days posttransfection. At the indicated time points, low-
molecular-weight DNA containing both input and replicated viral
DNA was isolated using Qiagen spin columns as described pre-
viously (Ziegler et al., 2004), digested with BamHI and DpnI
enzymes, resolved on 1% agarose gel and analyzed by Southern
blotting as described previously (Saribas et al., 2011).
Preparation of whole-cell and nuclear extracts for Western blotting
In parallel to the isolation of DNA samples from the transfected/
infected cells as described under replication assay, whole cell
extracts were also prepared at the indicated time points (see the
respective ﬁgure legends) as previously described (Sariyer et al.,
2011). Whole cell lysates were analyzed by Western blotting, using
an anti-agnoprotein polyclonal antibody as described under each
ﬁgure legend and described previously (Sadowska et al., 2003).
Northern blotting
Northern blotting was carried out as previously described
(Safak et al., 2002). Brieﬂy, SVG-A cells (2106 cell/75 cm2 ﬂask)
were separately transfected with different plasmid constructs
[Bluescript KS(+)-JCV Mad-1 WT, Bluescript KS(+)-JCV Mad-1
Agno Δ(34–36), Bluescript KS(+)-JCV Mad-1 Agno Δ(30–37) and
Bluescript KS(+)-JCV Mad-1 Agno Ala(34–36)] (8 mg/ﬂask), using
lipofectamine 2000 according to Manufacturer's recommendations
(Invitrogen). The plasmid constructs were digested with BamHI
to liberate the viral genome inserts from the vectors prior to
transfection. Total RNA was isolated from untransfected (SVG-A
alone), transfected cells (2.2107 cells) at speciﬁc time points as
indicated in the respective ﬁgure legend using the RNeasy Plus
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was treated with RNase free DNase I to remove the DNA contam-
ination prior to fractionation on a 1% agarose gel and transferred
onto a nitrocellulose membrane. The coding region of JCV Mad-1
VP1 was PCR-ampliﬁed, [32P]-radiolabeled and incubated with the
RNA blots as a probe to detect VP1-associated JCV transcripts.
RT-PCR and DNA sequencing
cDNA synthesis was carried out using SuperScript™ III one step
RT-PCR system (Invitrogen, Cat #: 12574-026). Brieﬂy, 300 ng total
RNA isolated for Northern blot samples was mixed with 1 ml of
oligo dT(12–18) (0.5 mg/ml) and 1 μl of dNTP mix (10 nM each dATP,
dCTP, dGTP and dTTP) and the reaction volume was brought up to
13 μl. The samples were then heated at 65 1C for 5 min and cooled
on ice for 1 min. After brief centrifugation, 4 μl of 5 First Strand
Buffer, 1 μl DTT (0.1 M) and 1 μl SuperScript™ III reverse transcrip-
tase (200 units/μl, Invitrogen) were added to each reaction and
mixed gently by pipetting. The reactions were then incubated at
55 1C for 1 h to synthesize cDNA. Reverse transcriptase was
inactivated by heating of the reaction samples at 70 1C for
15 min. Finally RNA complementary to the cDNA was incubated
with RNAse H (1 u/ml/reaction) (Invitrogen) at 37 1C for 30 min.
Speciﬁc PCR reactions were carried out as described under
respective ﬁgure legends. The puriﬁed PCR products were
sequenced by a commercial vendor (Genewiz, http://www.gene
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